Cargando…

Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with or without Systemic Sclerosis: A Meta-Analysis

BACKGROUND: Nintedanib is a potent intracellular inhibitor of tyrosine kinases and modulates the pathways involved in the development of fibrosis. We assessed nintedanib efficacy and safety in interstitial lung disease (ILD) patients. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Young Ho, Song, Gwan Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682577/
https://www.ncbi.nlm.nih.gov/pubmed/38033836
http://dx.doi.org/10.18502/ijph.v52i9.13561